Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2026
Institutional positions in Damora Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +40 vs. Q1 2026
- Shares held
- 64.5M
- +10.9M (+20.2%) vs. Q1 2026
- Total value
- $1.67B
- +$284.5M (+20.5%) vs. Q1 2026
- New holders
- 52
- 27 more added
- Sold out
- 12
- 9 more reduced
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 104 | $1.67B |
| Q1 2026 | 65 | $1.45B |
| Q4 2025 | 18 | $65.5M |
| Q3 2025 | 12 | $633.3K |
| Q2 2025 | 9 | $451.5K |
| Q1 2025 | 11 | $442.4K |
| Q4 2024 | 10 | $660.7K |
| Q3 2024 | 10 | $1.56M |
| Q2 2024 | 22 | $1.91M |
| Q1 2024 | 26 | $3.09M |
| Q4 2023 | 22 | $2.77M |
| Q3 2023 | 22 | $3.92M |
| Q2 2023 | 27 | $25.7M |
| Q1 2023 | 26 | $17.8M |
| Q4 2022 | 22 | $10.2M |
| Q3 2022 | 26 | $17.3M |
| Q2 2022 | 23 | $15.7M |
| Q1 2022 | 25 | $21.0M |
| Q4 2021 | 26 | $30.5M |
| Q3 2021 | 25 | $37.2M |
| Q2 2021 | 27 | $57.4M |
| Q1 2021 | 19 | $82.9M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Damora Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| VR Adviser, LLC | 3,603,595 | $93.7M | 2.84% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 3,783,000 | $98.4M | 0.88% | 00.0% | Unchanged |
| Fairmount Funds Management LLC | 8,713,000 | $226.6M | 14.98% | 00.0% | Unchanged |
| FMR LLC | 9,232,979 | $240.1M | 0.01% | +187,498+2.1% | Added |
| Millennium Management LLC | 0 | $0 | 0.00% | −471,646−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −282,436−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −169,818−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −110,441−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −76,338−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −55,232−100.0% | Sold out |
| Landscape Capital Management, L.L.C. | 0 | $0 | 0.00% | −24,456−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −17,293−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −11,420−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −10,824−100.0% | Sold out |
| Cannon Global Investment Management, LLC | 0 | $0 | 0.00% | −9,300−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −7,921−100.0% | Sold out |
| Janus Henderson Group PLC | – | – | – | – | Not filed |